AstraZeneca's Imfinzi shows promise in treating aggressive lung cancer
Drugmaker AstraZeneca said on Friday its blockbuster cancer drug Imfinzi showed "significant and clinically meaningful" improvement in the primary goals of a late-stage trial designed for an aggres...
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
AstraZeneca leads fallers echoing Wall Street's Medicaid surprise
AstraZeneca PLC (LSE:AZN) led the fallers on the main index, down 1.3% and echoing falls seen among US peers overnight. It follows surprise news that federal payment rates to Medicare insurers nex...
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.
Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Astrazeneca (AZN) concluded the recent trading session at $67.25, signifying a -0.74% move from its prior day's close.
7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years
Blue-chip stocks are associated with a low-beta, stable returns, and passive dividend income for investors. However, not all blue-chip stocks are comparable when it comes to returns over a time-frame.
AstraZeneca CEO Soriot on Pharmaceuticals in China
AstraZeneca CEO Pascal Soriot discusses the drugmaker's business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships in China. He speaks with Stephen Engle on the sidelines...
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.
2 More Potential Biotech Buyout Targets
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related pr...
3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar
In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Astrazeneca (AZN) closed at $65.86 in the latest trading session, marking a +0.02% move from the prior day.
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
Related Companies